81% Of China’s Generic Drug Applications Are Redundant
This article was originally published in PharmAsia News
Executive Summary
Chinese authorities received 2,095 generic registration applications in 2012, more than 81% of them are for generic versions of branded drugs that already have multiple approved generics.
You may also be interested in...
Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell
Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February.
Pharmacogenetic Tests: US FDA Tries Off-Label Approach To Guide Consumers
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports